SPRY Lowers Guidance
ARS Pharmaceuticals lowers FY26 cash operating expense guidance, shares trade lower
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARS Pharma Lowers 2026 Expense Guidance
ARS Pharma lowers 2026 cash operating expense guidance to $248M and reaffirms path to cash-flow breakeven in 2027